Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.

Background: There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE).

Objective: To evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE.

Methods: In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week(W) treatment period in DELTA 1 and 2 were treated on an as-needed basis with twice-daily delgocitinib for 36 weeks (n=801).

The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East Greenland.

Background: Hand eczema (HE) is described as a common disease in Greenland, but studies on its epidemiology and severity are lacking.

Objectives: To investigate the point prevalence and severity of HE among adults in East Greenland in relation to age, sex, and occupation.

Methods: In May 2022, we conducted a cross-sectional study in Tasiilaq, East Greenland.

Contact Allergy to Methacrylate Containing Nail Products: Lack of Impact of EU Legislation. An Audit on Behalf of the European Environmental Contact Dermatitis Research Group (EECDRG).

Background: There is a current fashion for the use of methacrylate-containing nail cosmetics that can induce allergic contact dermatitis. European Union (EU) legislation was introduced in 2021 that had the aim of preventing its development.

Objectives: To assess prevalence and exposures causing contact allergy to 2-hydroxyethyl methacrylate (HEMA) prior to and following implementation of the legislation.

Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS).

Introduction: Chronic Hand Eczema (CHE) is an inflammatory skin disease that causes significant impact on health-related quality of life (HRQoL). The Hand Eczema Impact Scale (HEIS) is a new patient-reported outcome (PRO) measure designed to assess the impact of CHE on key domains of HRQoL. This study aimed to develop and evaluate content and psychometric validity of the HEIS.